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Abstract
Background—Novel strategies are needed to increase retention in and uptake of prevention of 
mother-to-child HIV transmission (PMTCT) services in sub-Saharan Africa.
Objective—To determine whether small, increasing cash payments conditional on attending 
scheduled clinic visits and receiving proposed services can increase the proportions of HIV-
infected pregnant women who accept available PMTCT services and remain in care through six 
weeks postpartum.
Methods—Newly diagnosed HIV-infected women, ≤32 weeks pregnant, were recruited at 
antenatal care clinics in Kinshasa, Democratic Republic of Congo, and assigned in a 1:1 ratio to an 
intervention or control group using computer-based randomization. The intervention group 
received compensation on the condition that they attended scheduled clinic visits and accepted 
offered PMTCT services ($5, plus $1 increment at each subsequent visit), while the control group 
received usual care. Outcomes assessed included: 1) retention in care at six weeks postpartum, and 
2) to uptake PMTCT services, measured by attendance of all scheduled clinic visits and 
acceptance of proposed services through six weeks postpartum. Analyses were intent-to-treat.
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Results—Between April 2013 and August 2014, 612 potential participants were identified, 545 
were screened, and 433 were enrolled and randomized. At six weeks post-partum, the proportion 
of participants retained in care was higher in the intervention group than the control group 
(174/216, 80·6% vs. 157/217, 72·4%; risk ratio (RR), 1·11; 95% confidence interval (CI), 1·00–
1·24). The proportion of participants who attended all clinic visits and accepted proposed services 
was higher in the intervention group than the control group (146/216, 67·6% vs. 116/217, 53·5%; 
RR, 1·26; 95% CI, 1·08–1·48). Results were similar after adjusting for marital status, age, and 
education.
Conclusions—Among newly diagnosed HIV-infected women, small, incremental cash 
incentives resulted in increased retention along the PMTCT cascade and uptake of available 
services. The cost-effectiveness of these incentives and their effect on HIV-free survival warrant 
further investigation.
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INTRODUCTION
Achieving the President’s Emergency Plan for AIDS Relief (PEPFAR) goal of an AIDS-free 
generation has been reemphasized in PEPFAR 3.0.1 The current recommendations of 
lifelong triple antiretroviral therapy (ART) for all HIV-positive pregnant and breastfeeding 
women regardless of CD4 count (Option B+)2 requires that, beginning with the first 
antenatal care visit, HIV-infected mothers strictly adhere to a continuum of care known as 
the “prevention of mother-to-child transmission of HIV (PMTCT) cascade”.3 The PMTCT 
cascade includes attendance at regular clinic visits (at a minimum for ART refills), delivery 
in a health facility, and testing of the HIV-exposed infant (HEI) at six weeks, at nine months, 
and at the end of all breastfeeding (between 18–24 months). Monitoring data from early 
implementation of Option B+ in Malawi show that about one in six pregnant women 
initiated on ART at antenatal care (ANC) registration do not return to the clinic after their 
initial visit.4 A recent meta-analysis of women lost to follow-up (LTFU) across the “PMTCT 
cascade” indicated that 49% of HIV-infected pregnant women are LTFU between ANC 
registration and delivery, and 34% of mother-infant pairs are LTFU within three months of 
delivery.5 Half of all new episodes of HIV transmission to children are now estimated to 
occur during the breastfeeding period when the majority of lactating women are not 
receiving the prophylaxis necessary to prevent HIV transmission.6 Additionally, less than 
40% of HEIs are tested for HIV within the first two months of life in priority countries.7 
Thus, to achieve an AIDS-free generation, novel and effective strategies to reduce LTFU 
among HIV-infected women and their infants, and to fully maximize adherence to ART, are 
critically needed.
In resource-limited settings, transportation costs and opportunity costs have been identified 
as important barriers to PMTCT.1011 The provision of economic incentives has the potential 
to help women overcome economic barriers to care-seeking by compensating for 
transportation costs and opportunity costs of time. In addition, the tendency to place 
disproportionate weight on immediate costs and discount delayed benefits has been posited 
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as a reason for suboptimal decision-making in behavioral economics research,8,9,12 and may 
further limit PMTCT behaviors. Economic incentives can address these psychological 
barriers to health-seeking behavior as well, by creating immediate rewards that “nudge” 
individuals towards positive health behaviors.12 Positive behavioral responses to the 
provision of incentives would also be consistent with the construct of “perceived benefits” 
that would counter “perceived costs” in the Health Belief Model.13 While several recent 
studies have shown that incentive-based interventions, including conditional cash transfers, 
can be effective in promoting health behaviors in low- and middle-income countries,14–19 no 
studies have examined whether they can improve PMTCT behaviors and outcomes.
We conducted a randomized controlled trial to determine whether small, increasing cash 
payments conditional on attending scheduled clinic visits and receiving proposed services 
can increase the proportions of HIV-infected pregnant women who attend clinic visits and 
receive available PMTCT services through six weeks postpartum.
METHODS
Study settings and standard of care
The study was conducted in 89 maternal and child health (MCH) facilities in Kinshasa, the 
capital city of the Democratic Republic of Congo (DRC). Most clinics had been providing 
PMTCT services for at least two years.
At the time that study enrollment began in 2013, PMTCT services were delivered in the 
participating clinics through a decentralized model, with pregnant women receiving HIV 
counseling and testing as well as CD4 testing and results at the MCH clinic. All HIV-
infected women were eligible to initiate AZT immediately following receipt of their result. 
For those with CD4 >350, all subsequent care as well as HIV prevention and care for the 
HEI (daily NVP, cotrimoxazole, and DNA PCR testing) were delivered at the MCH clinic. 
For those with CD4 ≤350, referrals were made for treatment at the nearest ART center. To 
ensure linkages between MCH facilities and HIV clinics, HIV-infected trained volunteers 
counseled and accompanied women diagnosed with HIV. A mother-infant register – 
modeled after the WHO’s Three Interlinked Patient Monitoring Systems for HIV Care/ART, 
MCH/PMTCT (including malaria prevention during pregnancy), and TB/HIV: Standardized 
Minimum Data Set and Illustrative Tools – was used to track important HIV care events 
among HIV-infected pregnant women and subsequently their HEIs, from the first contact 
with the ANC clinic through 18 months after delivery.20 All HIV-infected women were 
required to visit the clinic at least once a month to collect their HIV drugs. Those visits were 
generally timed to match ANC and well-child clinic visits. All study activities were planned 
during these routine visits. Starting in early 2014, World Health Organization (WHO) 
Option B+2 was progressively implemented in the MCH clinics with ART available onsite.
Participants, randomization, and masking
Between April 2013 and August 2014, newly diagnosed HIV-infected women, ≤32 weeks 
pregnant, registering for ANC at one of the 89 clinics during the enrollment period were 
considered for participation in the study. Potential eligible participants who were severely ill, 
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did not intend to stay in Kinshasa through at least six weeks postpartum, who refused to 
participate, or did not speak French or Lingala (the common languages in Kinshasa) were 
excluded. During their first follow-up visit after ANC registration (generally between two 
weeks to one month after ANC registration), eligible participants were consented by a study 
nurse who was not part of the care-providing team. Consented participants were assigned to 
the intervention or control group in a 1:1 ratio, by use of a computer-generated 
randomization sequence with varying block sizes of four, six, and eight. To limit 
heterogeneity of follow-up time, consented women were randomized at the earliest visit 
between 28 and 32 weeks of gestation. At the randomization visit, after performing all study 
procedures for the visit including verifying the eligibility of the potential participant, the 
study staff opened an envelope that contained the participant’s group allocation (control or 
intervention) and a study identification number (PID), and recorded the PID on all study 
forms including the enrollment questionnaire and the study randomization form used by the 
cashier to pay out incentives. Envelopes were prepared by a statistician who was not 
associated with recruitment and follow-up, prior to the beginning of enrollment. Participants 
who lost their pregnancy before 28 weeks of gestation, failed to return to the clinic after 
initial diagnosis, or returned after 32 weeks of gestation were also excluded from the study.
The name of each participant and her assigned group were added to the list of participants 
maintained by a cashier at each facility, for payment purposes. Although it was not possible 
to conceal the intervention to participants and the study staff, clinical services were provided 
by clinic staff who were not part of the study team and were not informed of participants’ 
group assignments. Study staff were not involved in clinical care and participants were asked 
not to communicate their group assignment to clinical staff. Study personnel and clinic staff 
were trained and supervised to minimize differential treatment by randomization arm, with 
refresher meetings quarterly.
Intervention – conditional cash transfers
In addition to the standard of care described above, all participants randomized to the 
intervention group received small, escalating cash payments, starting at US $5 (US dollars 
are accepted in DRC) and increasing by $1 each visit, on the condition that they attended 
scheduled clinic appointments and completed the following actions (if requested): provide a 
blood sample for CD4 count and hemoglobin if needed, accept referral for ART if referred, 
deliver in a health facility, and at 6 weeks postpartum provide a blood sample for early infant 
HIV diagnosis. The intervention had a reset contingency wherein the escalating value of the 
incentive went back to its original value ($5) when the mother failed to complete any of the 
actions required at a specific visit. The maximum amount of incentive payments that any 
participant could receive through six months postpartum was $45. A small card attached to 
the ANC card was used to track completion of each conditionality for study participants 
without regard to randomization group. Attending nurses completed the cards and checked 
the corresponding boxes on the cards to indicate whether or not the conditionalities were 
completed. Actions that could not be completed for reasons beyond the control of 
participants (e.g., stock-outs) were checked as completed on the cards. The cards were 
completed for all participants irrespective of their randomization group. At the end of each 
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visit, participants took the cards to the cashier, who used them to determine the amount to be 
paid.
Outcome measures
Two primary outcomes were evaluated: 1) retention in care, defined as the proportion of 
participants in HIV care at six weeks postpartum without regard to reason of not being in 
care, and 2) to uptake PMTCT services through six weeks postpartum. Participants were 
considered to uptake PMTCT services if they met all the conditionalities: attended all their 
scheduled clinic visits (within five days of the scheduled date) from randomization through 
six weeks postpartum, including giving birth in a study clinic, and accepted all proposed 
services including providing blood samples for CD4 count and dried blood spot sample for 
DNA PCR testing at six weeks. The originally proposed primary outcomes “proportion of 
women who were adherent to all conditionalities” and “proportion of HIV-exposed infants 
who at their six week visit received extended NVP and cotrimoxazole and had a DNA PCR 
test” were refined to take into account constraints that were beyond the control of 
participants, such as lack of reagents for DNA PCR testing at the national laboratory.
Secondary outcomes assessed were 1) LTFU – the proportion of participants who were not 
in care at six weeks postpartum and whose whereabouts were unknown (participants who 
were dead, and participants who did not return to the clinic because they experienced a poor 
pregnancy outcome but could still be reached, were classified as not in care but not as 
LTFU), and 2) the proportion of HEIs who tested positive for HIV at six weeks. Only infants 
with available DNA PCR results were eligible for the latter outcome. All outcomes were 
documented in the mother-infant register.
Statistical analysis
Proportions in the intervention and control groups were compared using Pearson’s Chi-
square. Log-binomial models were used to estimate unadjusted risk ratios (RR) and 95% 
confidence intervals (CI) for each of the outcomes. Generalized estimating equations were 
used to adjust for potential clustering at the clinic level. Analyses were also adjusted for any 
baseline characteristic that was found to be imbalanced between groups or hypothesized as a 
strong predictor of a primary outcome. Baseline characteristics considered included: 
participant’s age in years, marital status (married/cohabitating or other), years of education, 
gestational age at enrollment, gravity (primigravida: yes or no), the way participants most 
often went to the clinic (walk or other), time it usually took to get to the clinic (in minutes), 
and socioeconomic status (SES). Principal components analysis was used to determine the 
SES measure, and included years of education, average number of household members per 
room (an indication of crowding), number of sleeping beds in the household, types of 
household water source (communal or private pipe), cooking fuel type (electrical stove, or 
wood/charcoal), and ownership status for several durable assets. The first component 
explained 27% of the variability in the data (factor score was categorized into SES quintile 
coded 0 to 4, with 0 corresponding to the richest quintile and 4 corresponding to poorest 
quintile).
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Subgroup analyses were conducted to determine the effects of providing incentives to 
participants with certain demographic and socioeconomic characteristics, timing of ANC 
registration, disclosure of HIV status, and mode of transport to clinic.
The sample size calculation was based on an expectation that the proportion of participants 
retained in care and accepting available PMTCT services in the control group would be 50% 
and that a difference of 15% would be observed due to the intervention g. To show this effect 
with 90% power (α=0.05), 454 participants were needed. LTFU was treated as not retained 
in care. All analyses were by intent-to-treat, with women kept in their randomized group 
independent of whether they actually received cash payments. All analyses were completed 
using SAS 9.3 (SAS Institute, Cary, NC). All tests were two-sided and used a 0·05 
significance level.
Role of the funding source and ethical approval
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication. The 
study was approved by the Institutional Review Board of the Ohio State University and the 
Ethical Committee of the Kinshasa School of Public Health. All participants provided signed 
informed consent. Written informed consent and interviews were carried out in Lingala or 
French.
RESULTS
Participants and recruitment flow
Between April 2013 and August 2014, 612 potential participants were identified. Of those, 
67 (10·9%) never returned to the clinic after HIV diagnosis. Of 545 screened, 48 did not 
meet the eligibility criteria and 64 were excluded (Figure 1). Primary reasons for 
ineligibility were late registration for ANC (visit after 32 weeks of gestation) (n = 22) and 
not being newly diagnosed with HIV (n=19). Primary reasons for exclusion included refusal 
to accept HIV-positive status (n = 22) and enrollment prior to 28 weeks but LTFU before 
randomization (n = 16). Overall, 433 women in 84 participating MCH clinics were 
randomized to the control (217) and intervention (216) groups. The median number of 
participants per clinic was 4 (interquartile range [IQR], 2–6) with 11 clinics contributing 
between 10 and 20 participants each.
Baseline characteristics
Participants in the two study groups had similar characteristics at baseline (Table 1). At 
baseline, participants had a median age of 29 years [interquartile range (IQR), 25–34], a 
median of 10 years of education (IQR, 8–12), and a median gestational age of 26 weeks 
(IQR, 22–28). Most participants (82·9%) were married or cohabitating. Participants reported 
a median one-way travel time to clinic of 20 minutes (IQR, 10–30) and slightly over half 
(56·6%) reported walking to their clinic. The median travel time was longer for those who 
did not walk (31 vs. 24 minutes, p = 0·05). The current pregnancy was the first for 12·9% of 
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participants. Two to four weeks following ANC registration, 23·3% had disclosed their HIV 
status to someone else, primarily to their partner or a family member.
Primary outcomes
Following randomization, all participants attended at least follow-up visit (Table 2). 
Comparisons of the intervention and control groups are reported in Table 3. At six weeks 
postpartum, 23·6% of participants (102/433) were not in HIV care. This included 6·2% 
(27/433) who had experienced a poor pregnancy outcome and 1·8% (8/433) who were still in 
care but refused HIV services. Participants in the intervention group, compared to those in 
the control group, were significantly more likely to be in HIV care [80·6% (174/216) vs. 
72·4% (157/217); unadjusted RR, 1·11; 95% CI, 1·00–1·24].
At six weeks postpartum, 67·6% of participants in the intervention group (146/216) had 
attended all of their scheduled visits on time and accepted all available PMTCT services, 
compared to 53·5% (116/217) in the control group; unadjusted RR, 1·26; 95% CI, 1·08–
1·48.
Adjusting for years of education, marital status, and the mode of transport to the clinic did 
not substantially change the results for either of the outcomes examined (Table 3).
Secondary outcomes
The intervention group was significantly less likely to be LTFU (10·8%, 23/216) than the 
control group (20·5%, 44/217), with an unadjusted RR of 0·53 (95% CI, 0·32–0·86). About 
half (n = 36) of total LTFU participants were lost before delivery. Of those, 12 (5·6%) were 
in the intervention group and 24 (11·1%) were in the control group. If the analysis was 
restricted to those LTFU before or at delivery, the unadjusted RR was 0·50 (95% CI, 0·24–
1·03).
DNA PCR test results were available for 292 infants including 152 and 140 from the 
intervention and control groups, respectively. Of those infants, five (3·3%) in the 
intervention group and six (4·3%) in the control group tested positive (unadjusted RR, 0·77; 
95% CI, 0·24–2·46).
Subgroup analysis
For retention in care, in all subgroups except for women who had disclosed their HIV status 
to someone (adjusted RR [aRR], 0·95; 95% CI, 0·79–1·13) and primigravida women (aRR, 
0·83; 95% CI, 0·65–1·08), retention was higher in the intervention group than the control 
group (Table 4). For uptake of PMTCT services, the effect of the intervention was strongest 
among participants in the poorest wealth quintile (aRR, 1·33; 95% CI, 1·01–1·76), those who 
walked to the clinic (aRR, 1·39; 95% CI, 1·15–1·69), those who initiated ANC after 20 
weeks of gestation (aRR, 1·29; 95% CI, 1·08–1·53), multigravida women (aRR, 1·39; 95% 
CI, 1·18–1·63), and women who had not disclosed their HIV status (aRR, 1·42; 95% CI, 
1·17–1·72).
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Amount of incentive payments
The total amount of incentive payments to participants in the intervention group ranged from 
$5 to $45, with a median of $26 (IQR, $18–$35). One participant randomized to the control 
group received incentive payments totaling $35 and was retained in care at six weeks 
postpartum. Based on the costs of the incentives alone and the measured differences in 
retention between the intervention and control groups, the intervention had a cost of $317 
per additional person retained in care (number needed to treat [NNT] = 12) or of $184 per 
additional participant with full uptake of PMTCT services (NNT = 7).
DISCUSSION
Retention and uptake of services along the PMTCT cascade are vital for reducing vertical 
transmission and achieving the global goal of an HIV-free generation. There is an urgent 
need for strategies that enhance the effectiveness of PMTCT interventions. In this 
randomized controlled trial, we found that offering HIV-infected pregnant women small, 
escalating cash incentives starting at 28 weeks of gestation led to increased retention in care 
at six weeks postpartum and higher complete utilization of PMTCT services (as measured 
by attendance of all clinic visits and receipt of available services through six weeks 
postpartum). We also found that participants who were offered incentives were less likely to 
be LTFU between 28 weeks of gestation and six weeks postpartum. The effects of the 
intervention on retention in care and on uptake of available services were stronger among 
participants in the poorest wealth quintile, those who walked to the clinic, multigravida 
women, and those who had not disclosed their HIV status, suggesting that conditional cash 
transfers made directly to these more vulnerable women might increase their control over 
financial resources as well as empower them to make decisions about utilization of needed 
health care services.
To our knowledge, this is the first trial to evaluate the effectiveness of financial incentives for 
improving retention in and uptake of PMTCT services. Our results are consistent with the 
theoretical rationale for using incentives to modify health behaviors, and with studies 
showing that incentive or compensation provision can be used to achieve increased uptake of 
HIV prevention services such as HIV testing,21 medical male circumcision,17 and linkage to 
HIV care.22 Our results are also consistent with studies in low- and high-income countries 
that report positive effects of incentives on school attendance,23,24 vaccination uptake,19 
smoking cessation,25 and weight loss.26 The results are also in contrast to recent studies that 
did not show effectiveness of incentives to promote ART adherence and retention in care in 
the US.27 Overall, however, the results expand the generalizability of findings from research 
on financial incentives to promote positive health behavior.
A novel feature of the incentive intervention evaluated in this study is the inclusion of a pre-
defined incentive schedule that started at $5 for the first visit and escalated by $1 for each 
subsequent visit, with a reset contingency whereby the incentive declined to $5 in case of a 
missed visit or not accepting services. Such an incentive scheme further incentivized 
continued retention in care and resembled schemes that have previously been used in 
contingency management interventions to promote continued abstinence from substance 
abuse in the US.28,29 The feasibility of implementing such an incentive scheme was 
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enhanced by the fact that this study focused on a clearly defined antenatal and postpartum 
period, and was conducted in a clinical setting.
This study had several limitations. First, a substantial number of potential participants (n = 
45) were not randomized either because they refused their HIV-infected status (n = 22), were 
LTFU before randomization (n = 26), or returned to clinic after the randomization window 
(n = 7). We do not know the impact of not including these potential participants on the 
results, however, these women were disproportionally poor (48% in the two poorest 
quintiles), suggesting that if the financial incentives were given at the first visit, some of the 
women who were LTFU may have stayed in care and some of those who returned late would 
have been more adherent, increasing the observed positive effect of the intervention. Second, 
a small sample size was enrolled in many clinics, meaning that treatment arms were not 
balanced among the clinics, with 14 clinics including only one participant and only 49 
clinics having balanced enrolment between the arms. Third, because of small sample sizes 
and limited statistical power, our comparisons of the intervention’s effects in different 
subgroups should be considered as exploratory. Fourth, the study did not examine whether 
alternative forms of conditional economic compensation (e.g., noncash, or lower/higher 
amounts) were less, equally, or more effective in increasing retention in care and uptake of 
services. Additional testing of such strategies in PMTCT settings is needed in order to 
identify the most efficient and effective strategies. Fourth, the intervention and follow-up 
was stopped at six weeks postpartum; thus, the effect of the intervention on retention in 
postpartum care remains to be fully evaluated. Finally, further testing is necessary to 
determine the generalizability of our intervention and results to settings outside the DRC. 
However, the fact that the effect appears to be stronger in poorer women and multigravida 
women suggests stronger effects could be observed in rural populations.
There has been tremendous progress in strengthening retention in PMTCT services in the 
participating clinics since the study was conceived, as illustrated by the high retention in 
care in the control group, which was higher than any of our planned scenarios for sample 
size calculation. However, it is important to point out that the PMTCT program in DRC 
continues to face severe logistical problems such as drug or test stock-outs, which explained 
the delay in getting the DNA PCR test results, even for participants who were fully adherent 
to scheduled visits and had provided a blood sample.
Given the growing recognition that factors such as low retention in care, linkage to care, and 
failure to deliver in a healthcare facility are limiting the effectiveness of available PMTCT 
interventions, the findings from this study suggest a promising, feasible approach that can 
help further the goal of reducing vertical transmission. Further consideration of logistical 
aspects associated with scaling up incentive-based interventions is needed, as is a formal 
cost-effectiveness analysis of the intervention that includes not only the costs of the 
incentives but also the administration costs and data on infections averted. Additionally, 
more in-depth examinations, including qualitative analyses, of the mechanisms by which 
cash incentive interventions increase desired PMTCT outcomes would enhance our 
understanding how these interventions work and improve our ability to design and scale up 
similar interventions for PMTCT and other health and social issues.
Yotebieng et al. Page 9













Strengths of this study include its implementation in a resource-limited setting and high- and 
low-volume clinics, suggesting that the results may be generalizable to similar contexts. The 
study also suggests the potential benefits of designing incentive schemes that offer repeated 
payments during a limited time period, include escalating payments to reward the 
achievement of target behaviors, and have reset contingencies to disincentivize missed visits.
Among newly diagnosed HIV-infected women, small, cash incentives resulted in 
significantly higher retention along the PMTCT cascade and better uptake of available 
services. The cost-effectiveness of these incentives and their effects on HIV-free survival 
warrant further investigation.
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Evidence before this study
The use of financial incentives, such as conditional cash transfers (CCTs), have been 
promoted as a promising way to achieve changes in health behavior in low- and middle-
income countries. Several randomized controlled trials (RCTs) have shown that 
incentive-based interventions can be effective in increasing uptake of preventive health 
services, including HIV testing and medical male circumcision, while there is less 
evidence in support of the effectiveness of incentives for promoting adherence to HIV 
treatment or retention in HIV care. However, no studies to date have assessed the 
effectiveness of CCTs on behaviors and outcomes related to the prevention of mother-to-
child-transmission of HIV (PMTCT). A 2012 systematic review of financial incentives 
for HIV prevention behaviors did not find any studies assessing the impact of financial 
incentives on PMTCT outcomes. On September 3, 2015, a PubMed search with the terms 
(cash transfer or financial incentive) and HIV yielded 30 RCTs, none of which was 
focused on PMTCT outcomes.
Added value of this study
Among newly diagnosed HIV-infected women in the Democratic Republic of Congo, 
small, incremental financial incentives resulted in significantly higher retention along the 
PMTCT cascade and significantly improved uptake of available services. Although the 
study was not powered to assess any difference in HIV-free survival, there was a slight 
tendency towards a lower transmission rate in the intervention group.
Implication
While the scalability and cost-effectiveness of CCTs as a strategy to optimize PMTCT 
outcomes warrant further investigation, the findings from this study suggest a promising, 
feasible approach that can help further the goal of reducing vertical transmission of HIV.
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Participants and recruitment flow
aWomen who gave birth in a facility other than where they received ANC (all deliveries with 
documented place of delivery occurred in a health facility). bWomen whose whereabouts 
was unknown at six weeks postpartum. cWomen seen at six weeks, but who refuse to 
continue HIV care. Abbreviations: ANC, antenatal care; LTFU, lost to follow-up
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Table 1
Characteristics of the 433 participants at enrollment in 87 maternal and child health clinics in Kinshasa, DRC 
between April 2013 and August 2014.
Study group
Overall Intervention Control
Age in years: median (IQR) 29·0 (25·0–34·0) 29·5 (26·0–34·0) 29·0 (25·0–34·0)
Gestational age in weeks: median (IQR) 26·0 (22·0–28·0) 26·0 (22·0–28·0) 26·0 (22·0–29·0)
Time to the clinic in minutes: median (IQR) 20·0 (10·0–30·0) 20·0 (10·0–30·0) 20·0 (15·0–30·0)
Maternal education in years: median (IQR) 10·0 (8·0–12·0) 10·0 (8·0–12·0) 10·0 (8·0–12·0)
Marital status: (n,%)
Married/cohabitating 358 (82·9) 178 (82·8) 180 (82.9)
Divorced/separated/widow/never married 74 (17·1) 37 (17.2) 37 (17.1)
Primigravida: (n,%)
Yes 56 (12·9) 30 (13.9) 26 (12.0)
No 377 (87·1) 186 (86.1) 191 (88.0)
Earliest ANC visit: (n,%)
<20 weeks 82 (18·9) 44 (20·4) 38 (17·5)
≥20 weeks 351 (81·1) 172 (79·6) 179 (82·5)
HIV disclosure to anyone: (n,%)
Yes 101 (23·3) 53 (24.5) 48 (22.1)
No 332 (76·7) 163 (75.5) 169 (77.9)
Wealth quintile:a (n,%)
Fifth (richest) 90 (20.8) 44 (20.4) 46 (21.2)
Fourth 86 (19·9) 42(19.4) 44 (20·3)
Third 87 (20·1) 47 (21.8) 40 (18.4)
Second 85 (19·6) 43 (19.9) 42 (19.4)
First (poorest) 85 (19·6) 40 (18.5) 45 (20.7)
Transport to clinic: (n,%)
Walk 245 (56·6) 118 (54.6) 127 (58.5)
Other 188 (43·4) 98 (45.4) 90 (41.5)
a
A wealth quintile score variable was created using principal component analysis (PCA). Twelve variables were included in the PCA: years of 
education, the average number of household members per room (an indication of crowding), the number of sleeping beds in the household, 
categories of household water source (communal or private pipe) and cooking fuel type (electrical stove, or wood/charcoal), and ownership status 
of the following durable assets: radio, television, mobile telephone, refrigerator, and car. Abbreviations: ANC, antenatal care; IQR, interquartile 
range.
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Table 2
Compliance to conditionalites at each follow-up visit after randomization among the 433 participants enrolled 
in 84 maternal and child health clinics in Kinshasa between April 2013 and August 2014
Intervention Control
Yesa No Yesa No
Follow-up visit 1 N = 216c N = 217c
Attended within the window period (+/− 5 days) 209 (96.8) 7 (3.2) 203 (93.6) 14 (6.4)
Provide blood sample (CD4 count/Hgb)* 211 (97.7) 5 (2.3) 211 (97.2) 6 (2.8)
Enrolled into HIV care and started ART* 215 (99.5) 1 (0.5) 213 (98.2) 4 (1.8)
All conditionalities completed 205 (94.9) 11 (5.1) 198 (91.2) 19 (8.8)
Follow-up visit 2 N = 188c N = 184c
Attended within the window period (+/− 5 days) 175 (93.1) 13 (6.9) 158 (85.9) 26 (14.1)
Provide blood sample (CD4 count/Hgb)* 179 (99.4) 1 (0.6) 166 (99.4) 1 (0.6)
Enrolled into HIV care and started ART* 180 (100.0) 0 166 (99.4) 1 (0.6)
All conditionalities completed 174 (92.6) 14 (7.4) 156 (84.8) 28 (15.2)
Follow-up visit 3 N = 95c N = 96c
Attended within the window period (+/− 5 days) 89 (93.7) 6 (6.3) 85 (88.5) 11 (11.5)
Provide blood sample (CD4 count/Hgb)* 92 (100.0) 0 89 (100.0) 0
Enrolled into HIV care and started ART* 92 (100.0) 0 89 (100.0) 0
All conditionalities completed 89 (93.7) 6 (6.3) 85 (88.5) 11 (11.5)
Follow-up visit 4 N = 17c N = 17c
Attended within the window period (+/− 5 days) 14 (82.4) 3 (17.6) 14 (82.4) 3 (17.6)
Provide blood sample (CD4 count/Hgb)* 14 (100.0) 0 15 (100.0) 0
Enrolled into HIV care and started ART* 14 (100.0) 0 15 (100.0) 0
All conditionalities completed 14 (82.4) 3 (17.6) 14 (82.4) 3 (17.6)
Delivery N = 204d N = 193d
Deliver in one of the study facilities 178 (87.3) 26 (12.7) 164 (85.0) 29 (15.0)
Provide blood sample (CD4 count/Hgb)* 203 (99.5) 1 (0.50) 183 (94.8) 10 (5.2)
Enrolled into HIV care and started ART* 204 (100.0) 0 189 (97.9) 4 (2.1)
All conditionalities completed 178 (87.3) 26 (12.7) 158 (81.9) 34 (18.1)
Six weeks postpartum visit N = 204c N = 193c
Attended within the window period (+/−5day) 166 (81.4) 38 (18.6) 144 (74.6) 49 (25.4)
Provide blood sample (CD4 count/Hgb)* 173 (99.4) 1 (0.6) 153 (97.5) 4 (2.5)
Enrolled into HIV care and started ART* 174 (100.0) 0 156 (99.4) 1 (0.6)
DBS for early infant diagnosis* 172 (98.9) 2 (1.2) 155 (98.7) 2 (1.3)
All conditionalities completed 164 (80.4) 40 (19.6) 138 (71.5) 55 (28.5)
a
For blood sample, participants were classified as compliant if they provided a blood sample at a previous or current visit, or if they accepted to a 
provide blood sample even if for some reason the sample was not collected. For Enrollment into HIV care and initiation of ART, participant were 
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considered to be adherent if they were not referred (CD4>350, or missing), if they have accepted the referral (first visit when CD4 visit became 
available), or subsequently if they have registered in the HIV care program and was receiving the best available regiment they were eligible to.
b
Does not include loss to follow-up (LTFU). Overall, all participants attended at least one follow-up visit after randomization; in the intervention 
group, 6, 3, and 3 participants were LTFU after the first, second, and third follow-up visits, respectively, compared to 15, 7, and 2 participants in the 
control group.
c
include all participants eligible for the visit.
d
Do not include the 36 who were known to no longer be in care at the time of delivery.
*
Only include participant who attended the visit
Abbreviations: DBS = Dried blood spot; Hgb = Hemoglobin
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